Unknown

Dataset Information

0

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.

ABSTRACT:

SUBMITTER: Oelschlaegel U 

PROVIDER: S-EPMC4740451 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.

Oelschlaegel U U   Alexander Röhnert M M   Mohr B B   Sockel K K   Herold S S   Ehninger G G   Bornhäuser M M   Thiede C C   Platzbecker U U  

Leukemia 20150624 2

Similar Datasets

Unknown CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).
| S-EPMC4744770 | biostudies-literature
Unknown Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes.
| S-EPMC7246771 | biostudies-literature
Unknown Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
| S-EPMC4937206 | biostudies-literature
Unknown p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
| S-EPMC4040908 | biostudies-literature
Unknown Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.
| S-EPMC6880887 | biostudies-literature
Unknown Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach.
| S-EPMC7922695 | biostudies-literature
Unknown Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
| S-EPMC7932918 | biostudies-literature
Unknown Clonal evolution in myelodysplastic syndromes.
| S-EPMC5530598 | biostudies-literature
Unknown Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
| S-EPMC3677141 | biostudies-literature
Unknown "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
| S-EPMC9061286 | biostudies-literature